Pharmasaga Co. Ltd. (7878)

Overview

Pharmasaga Co. Ltd. is a biotechnology company based in Taiwan, renowned for its specialization in innovative therapeutics aimed particularly at addressing metabolic diseases like type 1 and type 2 diabetes. The company's lead product, PS1, stands out due to its promising curative capabilities and is currently progressing through clinical trials in both Taiwan and the United States, with imminent plans for Phase II studies. Furthermore, Pharmasaga emphasizes novel drug discovery and has been recognized for its contributions to the biotech field, having received accolades such as the 2025 Taipei Biotech Award for Innovative Technology. Additionally, the company engaged in international collaborations and participated in the North America BIO Convention startup competition, underlining its commitment to addressing unmet healthcare needs across all age groups. As a publicly traded entity on the Emerging Stock Market, Pharmasaga Co. Ltd. plays an instrumental role in enhancing Taiwan's stature in global biopharmaceutical innovation, while actively maintaining communications with investors and stakeholders through dedicated channels.

Products and Services

• PS1 - Innovative Diabetes Drug

  This flagship product is designed with a focus on metabolic diseases, particularly diabetes types 1 and 2. PS1 has shown significant curative potential in preliminary studies and is currently advancing through various phases of clinical trials, showcasing the company’s commitment to delivering effective therapeutic solutions.

• Novel Drug Discovery

  Pharmasaga actively engages in the discovery of new pharmaceuticals, emphasizing innovation to meet the needs of patients suffering from metabolic diseases. This ongoing research is aimed at identifying unique therapeutic targets and developing new treatment modalities.

• Clinical Trials

  The company conducts rigorous clinical trials in line with international standards to ensure the efficacy and safety of its products. Currently, PS1 is undergoing critical phases of testing in Taiwan and the United States, paving the way for Phase II studies.

• International Collaborations

  Pharmasaga actively collaborates with global partners, enhancing its research capabilities and broadening its impact on the biopharmaceutical industry. These collaborations contribute to the company's innovative approach and help tackle complex healthcare challenges.

• Investor Relations

  As a company listed on the Emerging Stock Market, Pharmasaga maintains transparency and open communication with its investors. It engages stakeholders through dedicated channels, ensuring that they remain informed about advancements and strategic directions of the company.